Form 4: United Therapeutics EVP Paul Mahon Executes Stock Options and Sells Shares Under 10b5-1 Plan

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 7, 2024, Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, exercised stock options to acquire 6,000 shares of common stock at a price of $117.76 per share.
• Following the exercise, Mahon sold 3,000 shares at a weighted average price of $236.9015, 2,700 shares at a weighted average price of $237.7591, and 300 shares at $238.85.
• These transactions were executed under a Rule 10b5-1 trading plan established on March 17, 2023.
• After these transactions, Mahon directly owns 36,599 shares of United Therapeutics common stock and 60,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were pre-planned under a Rule 10b5-1 trading plan and do not necessarily reflect a change in the executive's view of the company's prospects.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are common and are often scrutinized by investors to gauge management's sentiment about the company's future prospects. Transactions under 10b5-1 plans are generally viewed as less informative since they are pre-planned.

Comparison to Industry Standards

• Executive compensation practices, including stock options and trading plans, are common across publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Comparing Mahon's transactions to those of executives at similar-sized companies like BioMarin Pharmaceutical or Vertex Pharmaceuticals would provide context on the scale and frequency of such activities.
• The use of Rule 10b5-1 plans is a standard practice to allow insiders to sell shares without raising concerns about insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price due to the sale of shares.
• However, the pre-planned nature of the sales under the 10b5-1 plan should mitigate concerns about insider trading or a negative outlook from the executive.

Key Dates